ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $43.32M (cash outflow) fell 32.7% year over year, behind the +14.0% change in trailing-twelve-month net income. Sequentially, it rose 21.9% from the prior quarter. Over 3 fiscal years it compounded at +65.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$145.74M (-12.4%) for the fiscal year ending Dec 2026, a slowdown from the +106.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$43.32M+21.9% QoQ
- Last fiscal yearDec 2025
- -$166.31M+106.6% YoY
- LTMMar 2026
- -$145.24M+14.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -32.7% | +41.7% | +74.5 pp |
| 1 year | +106.6% | -12.4% | -119.0 pp |
| 3-year CAGR | +65.2% | -17.9% | -83.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (166.31M) USD
- Year-over-year change
- -106.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (166.31M) | -106.6% |
| FY2024 | 2024-12-31 | (80.49M) | -16.1% |
| FY2023 | 2023-12-31 | (69.33M) | -87.9% |
| FY2022 | 2022-12-31 | (36.91M) | +28.5% |
| FY2021 | 2021-12-31 | (51.61M) | — |
Net Income vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 net income of $145.24M is the 5th largest of the 11 companies compared; the peer median is $87.16M.
- Its year-over-year change of +14.0% is the 6th highest of 11, against a peer median of +18.9%.
- Over three fiscal years its annual growth of +65.2% compares with a peer median of +25.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $860.62M | +42.9% | +62.5% | 35.3% | |
| LTM Jun 2025 | $466.88M | +1212.4% | — | 77.5% | |
| LTM Sep 2026 | $307.94M | +141.2% | -20.0% | — | |
| LTM Jun 2026 | $188.21M | -11.4% | -26.6% | 41.9% | |
| LTM Mar 2026 | $145.24M | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $140.06M | -54.4% | +24.7% | 62.2% | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $131.11M | +36.0% | +29.4% | — | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $43.21M | -948.8% | — | — | |
| LTM Mar 2026 | $24.38M | -35.9% | +2396.3% | 10.7% | |
| Peer median (excluding AVBP) | $87.16M | +18.9% | +25.0% | 52.0% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.